The investigational drug, vadadustat, is a synthetic, orally bioavailable hypoxia inducible factor prolyl-hydroxylases (HIF-PHs) inhibitor and is showing promise as a therapeutic option for treating anemia in patients with chronic kidney disease. The Bobrow-Eltzschig collaboration will evaluate the efficacy of vadadustat as a pharmacological treatment for acute respiratory distress syndrome in hospitalized COVID-19 patients.
Vadadustat is designed to mimic the body’s response to low oxygen levels (for example, at high-altitudes) which include increasing red blood cell production and improved oxygen delivery to the body’s organs.
Currently, the 18-month trial has received funding including industry support from Akebia Therapeutics, the COVID-19 Pilot Project Award sponsored by the Center for Clinical and Translational Sciences at UTHealth, and the newly awarded Peer-Reviewed Medical Research Program Clinical Trial Award for Emerging Viral Diseases and Respiratory Health from the Department of Defense.
|Dr. Bentley Bobrow|
|Paulina Sergot, MD||Samuel D. Luber, MD, MPH|
|David Robinson, MD, MS, MMM||Elizabeth Jones, MD|